Morningstar

Mineralys Therapeutics Inc MLYS

Morningstar Rating
Unlock
Stock XNAS Rating as of
$12.78 −0.04 (0.31%)
View Full Chart
As of Cboe BZX Real-Time Price Open

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
MLYS is trading at a 560% premium.
Price
$12.76
Fair Value
$57.60
Uncertainty
Extreme
1-Star Price
$857.25
5-Star Price
$9.69
Economic Moat
Mjbwl
Capital Allocation
—

News

View All

Trading Information

Previous Close Price
$12.82
Day Range
$12.65–12.84
52-Week Range
$5.89–16.96
Bid/Ask
$12.59 / $12.89
Market Cap
$635.51 Mil
Volume/Avg
3,556 / 180,772

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
—
Total Number of Employees
28
Website
https://mineralystx.com

Comparables

Valuation

View More
Metric
MLYS
LBPH
CTNM
Price/Earnings (Normalized)
 ———
Price/Book Value
 2.194.812.11
Price/Sales
 ———
Price/Cash Flow
 ———
Price/Earnings
MLYS
LBPH
CTNM

Financial Strength

Metric
MLYS
LBPH
CTNM
Quick Ratio
 10.9620.6958.48
Current Ratio
 11.2020.9558.92
Interest Coverage
 ———
Quick Ratio
MLYS
LBPH
CTNM

Profitability

Metric
MLYS
LBPH
CTNM
Return on Assets (Normalized)
 −37.54%−35.81%−18.15%
Return on Equity (Normalized)
 −39.61%−38.49%−871.68%
Return on Invested Capital (Normalized)
 −44.88%−43.40%−892.99%
Return on Assets
MLYS
LBPH
CTNM

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
NhgcbhqjwYhls$518.0 Bil
 Vertex Pharmaceuticals Inc
VRTX
LdxsjhtZlyjpb$119.3 Bil
 Regeneron Pharmaceuticals Inc
REGN
YmzlqmhdJhzlpj$114.7 Bil
 Alnylam Pharmaceuticals Inc
ALNY
XyzmdtnrRznxrg$34.9 Bil
 argenx SE ADR
ARGX
BydzpnjwsMntz$32.9 Bil
 BioNTech SE ADR
BNTX
ZwqlsgmcjSczp$28.3 Bil
 Moderna Inc
MRNA
TvyvgplccJgtg$24.3 Bil
 United Therapeutics Corp
UTHR
LcvtrchsHzq$15.7 Bil
 Biomarin Pharmaceutical Inc
BMRN
DzpmrhbTxnwqnz$13.3 Bil
 Incyte Corp
INCY
ZqjksvklNdtqfz$13.0 Bil

Sponsor Center